Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

The SCIENCE trial was conducted at 14 centers in China and included 146 patients who ... Eligible patients had thoracic ESCC, had received no prior treatment, and were clinically staged as locally ...